Project description
Ground-breaking device detecting respiratory changes
Many at-risk patients such as those suffering from chronic obstructive pulmonary disease lack constant and accurate monitoring throughout their condition. This can have a detrimental effect on their health in addition to burdening the already strained healthcare systems. The EU-funded SenseGuard project has set out to identify the technical and business requirements needed to deliver a commercial version of SenseGuard™ – an innovative wireless wearable device that employs a unique nanosensor-based technology. This technology enables the continuous and non-invasive monitoring of lung function from a patient's normal breathing, identifying the subtle changes in a patient’s respiratory condition so that healthcare professionals can take the necessary measures.
Objective
Respiratory rate is a vital sign used to monitor the progression of illness both in hospitals and at home, particularly when dealing with at-risk patients. The continuous monitoring is key for patients with respiratory conditions (i.e. asthma), Chronic Obstructive Pulmonary Diseases (COPD) or pneumonia, with cardiovascular conditions, as well as elderly with comorbidities and prematurely born babies or babies with respiratory conditions.
SenseGuard respiratory monitoring device - is a decision support tool that assists practitioners in better monitoring patients with respiratory conditions like and at risks of deterioration. SenseGuard enables effective generation of alerts to clinical personnel, at the earliest moment following a change in patient’s status, at the hospital or at home. Due to its direct and high-resolution respiratory sensors, SenseGuard is able to continuously monitor pulmonary function on a breath-to-breath basis, unmatched by other technologies. SenseGuardTM can effectively monitor all at-risk patients.
NanoVation is an Israeli SME, founded in 2014, which develops and integrates nanomaterial-based sensors for medical applications and general purposes. Run by an experienced and multi-disciplinary team, NanoVation was granted several EU and non-EU projects, one of which awarded the 2018 Innovation Award by the European Commission. So far, NanoVation has raised and invested more than € 2.5M into the development of SenseGuard. To have it fully projected at a European and global level, NanoVation needs a further investment of €2.2M to complete product development and set up a solid EU value chain.
The proposed work in Phase 1 of the SME instrument fits into the company overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of SenseGuard and its market uptake.
Fields of science
- natural sciencescomputer and information sciencesinternetinternet of things
- medical and health scienceshealth sciencespublic health
- medical and health sciencesclinical medicinepneumologyasthma
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensors
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
3009500 Ramay Ishai
Israel
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.